Tesofensine (NS2330) is a novel triple monoamine reuptake inhibitor (TRI) that potently inhibits the presynaptic reuptake of serotonin, norepinephrine, and dopamine, increasing synaptic concentrations of all three neurotransmitters. Originally developed by NeuroSearch A/S for Parkinson's disease and Alzheimer's disease, tesofensine was repurposed for obesity treatment after consistent dose-dependent weight loss emerged as an 'adverse event' in neurological trials.
Clinical research demonstrates tesofensine produces approximately twice the weight loss of currently marketed anti-obesity medications, with phase II trials showing 9-11% body weight reduction over 24 weeks at therapeutic doses. Over 1,000 patients have participated in clinical trials investigating tesofensine for obesity, neurological disorders, and metabolic research, with publications spanning pharmacology, neuroscience, endocrinology, and clinical medicine.
The compound belongs to the phenyltropane structural class and features an 8-azabicyclo[3.2.1]octane core with a bis(4-chlorophenyl)methoxy substituent conferring high lipophilicity and monoamine transporter affinity. Tesofensine demonstrates exceptional pharmacokinetic stability with an extraordinarily long terminal half-life of approximately 234 hours (~9.75 days) in humans, enabling once-daily dosing with stable steady-state plasma concentrations.
IMPORTANT: This research-grade material is for in vitro laboratory applications only. Currently in Phase III clinical development; FDA orphan drug designation granted for Tesomet in Prader-Willi syndrome and hypothalamic obesity. Not approved for therapeutic use.
